We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.16B
1-Year Est. Return 67.93%
This Fund
S&P 500
This Quarter Est. Return
-6.06%
1 Year Est. Return
+67.93%
3 Year Est. Return
-39.17%
5 Year Est. Return
-45.89%
10 Year Est. Return
–
AUM
$2.38B
AUM Growth
-$279M
Cap. Flow
+$52.4M
Cap. Flow %
2.21%
Top 10 Hldgs %
99.67%
Holding
12
New
–
Increased
3
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
MCRB icon
Seres Therapeutics
MCRB
+$44.7M
2
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$5.69M
3
CDAK
Codiak BioSciences, Inc. Common Stock
CDAK
+$1.96M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$21.5B
$1.52B 64.14%
12,886,743
– –
SANA icon
2
Sana Biotechnology
SANA
$885M
$205M 8.65%
34,239,018
– –
MCRB icon
3
Seres Therapeutics
MCRB
$48.1M
$148M 6.25%
1,155,852
+436,912
+61% +$44.7M
OMGA
4
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$140M 5.91%
25,902,269
– –
FHTX icon
5
Foghorn Therapeutics
FHTX
$285M
$109M 4.58%
12,674,120
– –
EVLO
6
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$105M 4.44%
2,521,366
– –
DNLI icon
7
Denali Therapeutics
DNLI
$3.67B
$80.4M 3.38%
2,619,968
– –
AXLA
8
DELISTED
Axcella Health Inc. Common Stock
AXLA
$32.3M 1.36%
754,711
– –
RUBY
9
DELISTED
Rubius Therapeutics, Inc
RUBY
$16.6M 0.7%
38,506,526
– –
SYRS
10
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$6.4M 0.27%
993,848
+699,999
+238% +$5.69M
SGTX
11
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$5.18M 0.22%
797,721
– –
CDAK
12
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$2.76M 0.12%
3,540,636
+933,333
+36% +$1.96M

Similar funds

AC
AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return
BI
Bramshill Investments Naples, Florida $1.16B AUM 0.86% 1-Year Est. Return
SCP
Sandhill Capital Partners Buffalo, New York $1.16B AUM 12.37% 1-Year Est. Return
SFG
SNS Financial Group Minneapolis, Minnesota $1.16B AUM 13.88% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.16B AUM 25.7% 1-Year Est. Return
AMI
Amica Mutual Insurance Providence, Rhode Island $1.16B AUM 21.34% 1-Year Est. Return
FFP
FourThought Financial Partners Venice, Florida $1.16B AUM 24.95% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Flagship Pioneering's Q3 2022 Portfolio in Review

As of Q3 2022, Flagship Pioneering held 12 positions worth $2.38B, down 11% from $2.65B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2022: portfolio turnover was 0%. Flagship Pioneering opened no new positions and made no exits, leaving the 12-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Flagship Pioneering added most to Seres Therapeutics in Q3 2022, an estimated $44.7M increase.
  • Flagship Pioneering's ten largest holdings make up 100% of its $2.38B portfolio in Q3 2022.
  • Flagship Pioneering opened 0 new positions and closed 0 in Q3 2022.
  • Flagship Pioneering's portfolio value fell 11% quarter-over-quarter to $2.38B.

Based on Flagship Pioneering's 13F filing for Q3 2022, filed 14 Nov 2022.